About this trial
LifeBioMEMORY (LBM) is a reminiscence therapy (RT) mobile application that captures older adults' life stories in their own voices to promote social engagement and psychosocial well-being. This study will develop and evaluate an enhanced multilingual LBM app for community-dwelling, diverse older adults with mild cognitive impairment (MCI) or at risk of MCI and their informal caregivers, including Hispanic/Latino, Asian American (as one of subgroups, Korean), Black or African American, and non-Hispanic White populations. The app provides culturally tailored life story prompts with audio and visual cues to encourage reminiscence and storytelling. The intervention aims to improve quality of life, reduce depressive symptoms and loneliness, and strengthen caregiver-care recipient relationships, with the potential to provide an accessible, non-pharmacological approach to supporting cognitive and emotional well-being.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
Self-identified as Hispanic/Latino, Korean, Black/African American, and Non-Hispanic White
Speak and read Spanish, Korean, or English
Aged 60 years and older, with Montreal Cognitive Assessment (MoCA) test scores ranging 18-30 (with MCI: 18-25, or at risk for MCI: 26-30)
Have a local or in-home informal caregiver who can participate who is age 18 or older
Trial design
Parallel
Treatments tested in this trial
LifeBio Memory (LBM) digital reminiscence intervention
Other interventionLifeBioMEMORY (LBM) is a multilingual digital reminiscence therapy platform that guides older adults through life story sharing using culturally relevant prompts, photos, and voice recording in Spanish, Korean, or English. The app includes "My Story" and "Fun Things to Do" features to support reminiscence and engagement while capturing personal narratives. Using machine learning, LBM generates personalized Life Story Books and summaries in the preferred language of the older adult and informal caregiver, with electronic and printed copies available. The intervention is designed to promote social engagement, strengthen caregiver relationships, and support person-centered care.
Treatment groups
Trial outcomes
Primary outcomes
Primary Outcome
Health-Related Quality of Life (SF-12 Physical and Mental Component Summary Scores)
Secondary outcomes
Center for Epidemiologic Studies Depression Scale (CES-D)
The Center for Epidemiologic Studies Depression Scale (CES-D) measures depressive symptoms. Total scores range from 0 to 60, with higher scores indicating greater depressive symptoms (worse outcome).
Relationship Closeness Scale (RCS)
The Relationship Closeness Scale (RCS) measures perceived emotional closeness and relationship quality between the caregiver and care recipient. Total scores range from 6 to 24, with higher scores indicating greater relationship closeness (better outcome).
UCLA Loneliness Scale
The 3-Item UCLA Loneliness Scale (UCLA-LS-3) measures perceived loneliness and social isolation. Total scores range from 3 to 9, with higher scores indicating greater loneliness (worse outcome).Time Frame: Assessments will be conducted at baseline, 6 weeks, and 10 weeks.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
George Mason University
Lead sponsor
National Institute on Aging (NIA)
Collaborator
This trial is not recruiting at the moment. You can still explore other options: